Multiple myeloma (MM) is a plasma cell malignancy preliminary localized in the bone marrow and characterized by its capacity to disseminate. IL-6 and IGF-1 have been shown to mediate proliferative and anti-apoptotic signals in plasmocytes. However, in primary plasma-cell leukemia (PCL) and in end-stage aggressive extramedullar disease, the cytokine requirement for both effects may be not mandatory. This suggests that constitutive activation of signaling pathways occurs. One of the signaling pathways whose deregulation may play an oncogenic role in MM is the phosphatidylinositol 3-kinase (PI 3-K) pathway. In human growth factorindependent MM cell lines OPM2 and RPMI8226, we show that the PI 3-K inhibitors LY294002 and Wortmannin strongly inhibited cell proliferation, whereas inhibition of the mammalian Target Of Rapamycin (mTOR)/P70-S6-kinase (P70 S6K ) pathway with rapamycin or of the Mitogen-Activated Protein Kinase (MAPK) pathway with PD98059 had minimal effect on proliferation. In both cell lines, constitutive activation of the PI 3-K/Akt/FKHRL-1, mTOR/P70 S6K and MAPK pathways was detected. LY294002 inhibited phosphorylation of Akt, FKHRL-1 and P70 S6K but had no effect on ERK1/2 phosphorylation, indicating that the PI 3-K and MAPK pathways are independent. IGF-1 but not IL-6 increased phosphorylation of Akt, FKHRL-1 and P70 S6K . Purified plasmocytes from four patients with MM and two patients with primary PCL were studied. In three of them including the two patients with PCL, constitutive phosphorylation of Akt, FKHRL-1 and P70 S6K was present, inhibited by LY294002 and enhanced by IGF-1. In these patients with constitutive Akt activation, normal PTEN expression was detected. PI 3-K inhibition induced caspase-dependent apoptosis as confirmed by inhibition with the large spectrum caspase inhibitor Z-VAD-FMK and cleavage of pro-caspase-3. Both cell lines spontaneously expressed Skp2 and cyclin D1 proteins at high levels but no p27
Kip1 protein.
In the presence of LY294002, cell-cycle arrest in G0/G1 was observed, p27 Kip1 protein expression was up-regulated whereas the expression of both Skp2 and cyclin D1 dramatically diminished. PI 3-K-dependent GSK-3a/b constitutive phosphorylation was also detected in OPM2 cells that may contribute to high cyclin D1 expression. Overall, our results suggest that PI 3-K has a major role in the control of proliferation and apoptosis of growth factor-independent MM cell lines. Most of the biological effects of PI 3-K activation in these cell lines may be mediated by the opposite modulation of p27 Kip1 and Skp2 protein expression. Moreover, constitutive activation of this pathway is a frequent event in the biology of MM in vivo and may be more frequently observed in PCL.
Introduction
Multiple myeloma (MM) is an incurable malignancy of terminal B-cells accounting for approximately 1 to 2% of all human cancers. The survival and proliferation of MM cells depend on a supportive micro-environment. Cytokines such as IL-6 and IGF-1 support cell growth and prevent apoptosis of the plasmocytes (Ferlin et al., 2000; Freund et al., 1993; Ge and Rudikoff, 2000b; Klein et al., 1995) . IL-6 and IGF-1 produced in the bone marrow have been shown to activate both the PI 3-K and MAPK pathways in MM cells (Ge and Rudikoff, 2000b; Hideshima et al., 2001; Li et al., 2000; Tu et al., 2000) . These two signaling pathways have been linked to cancer. Human MM cell lines derived from patients with aggressive extramedullar MM disease are frequently growth factor-independent for their proliferation, suggesting that constitutive activation of both proliferative and anti-apoptotic signaling pathways occurs.
PI 3-K are a family of lipid kinases that phosphorylate the 3'-OH group of the inositol ring in inositol phospholipids. Class I PI 3-K are heterodimers which consist of a catalytic subunit p110 and a regulatory subunit p85. Proteins containing a pleckstrin-homology (PH) domain specifically associate to polyphosphoinositides. PH domains are found in numerous proteins, including the protein-serine/threonine kinase Akt/ protein kinase B (PKB) which is the main downstream target of PI 3-K (Datta et al., 1999) . The mechanisms of Akt activation are not completely understood, but the following model can be proposed. Production of PtdIns(3,4,5)P3 and PtdIns(3,4)P2 in response to PI 3-K activation causes translocation of Akt to the inner membrane in contact with active phosphoinositidedependent protein kinase 1 (PDK-1) (Toker and Newton, 2000) . The interaction of the Akt PH domain with 3'-phosphoinositides probably induces conformational changes to Akt, exposing its two main phosphorylation sites, Thr 308 and Ser 473. In a later phase, activated Akt acts on numerous different substrates implicated in the regulation of apoptosis and cell cycle, including the pro-apoptotic protein Bad (Datta et al., 1997) , the cyclic AMP response element binding protein (CREB) and the transcription factor FKHRL-1 of the Forkhead family . Akt-mediated phosphorylation of FKHRL-1 inhibits its transcriptional activity. The unphosphorylated form of FKHRL-1 positively regulates the transcription of genes coding for the Fas-ligand , the proapoptotic Bim (Dijkers et al., 2000b) and the cyclindependent kinase inhibitor p27
Kip1 proteins (Dijkers et al., 2000a; Medema et al., 2000) . P27
Kip1 stability is regulated by the F-box protein (Fbp) Skp2, a component of the ubiquitin E3 ligase SCF Skp2 (Nguyen et al., 1999) .
Phosphorylation of p27
Kip1 on Thr 187 by active cyclin E/Cdk2 complexes creates a binding site for Skp2.
Ubiquitination of p27
Kip1 by SCF Skp2 results in degradation of p27
Kip1 by the proteasome in the G1/S phase of the cell cycle, and causes cell cycle progression (Sutterluty et al., 1999; Tsvetkov et al., 1999) . P70 S6K is activated by multisite phosphorylation, which include PDK-1 phosphorylating the active loop of P70 S6K as well as rapamycin-sensitive mTOR, which appears to regulate Thr389 phosphorylation (Alessi et al., 1998; Pullen et al., 1998) . P70 S6K is involved in protein translation mainly through the phosphorylation of the 40S ribosomal protein subunit S6. P70 S6K plays a role in the regulation of the G1/S checkpoint of the cell cycle (Lane et al., 1993) , by upregulation of cyclin D3 and subsequent phosphorylation of Rb and p107 (Brennan et al., 1999; Feng et al., 2000) . P70
S6K may also be able to inhibit apoptosis (Harada et al., 2001; Hosoi et al., 1999) .
Another important substrate of Akt is the glycogen synthase kinase-3 (GSK-3) protein, whose function is inhibited by its Akt-mediated phosphorylation. GSK-3 negatively regulates cyclin D1 expression through transcriptionnal control of its gene and the control of its degradation by the proteasome (Diehl et al., 1998) .
In this report, we have studied the biochemical mechanisms controlling the proliferation and apoptosis in factor-independent human MM cell lines and their in vivo relevance in primary plasmocytes. We observed that constitutive activation of the PI 3-K/Akt/ FKHRL-1 and mTOR/P70 S6K pathways are frequently observed both in vitro and in vivo. Inhibition of the PI 3-K/Akt/FKHRL-1 signaling pathway strongly reduces proliferation and induces apoptosis. Inhibition of the mTOR/P70 S6K pathway has minimal effect on proliferation and only a modest effect on apoptosis. Finally, our results suggest that many of the oncogenic effects of PI 3-K in MM may be mediated through the low expression of the p27
Kip1 protein with a concomitant high expression of the F-box protein Skp2.
Results
The PI 3-K pathway contributes to the proliferation of factor-independent MM cell lines
In order to determine the signaling pathways implicated in the proliferation of factor-independent MM cell lines, we studied the proliferation of the human OPM2 and RPMI8226 cell lines in the presence of four inhibitors : LY294002 and Wortmannin, two inhibitors of PI 3-K; rapamycin, a macrolide antibiotic that selectively inhibits the activity of mTOR; PD98059, a specific inhibitor of the ERK1/2 MAPK pathway. Figure 1 indicates that only LY294002 and Wortmannin dramatically inhibited proliferation of both cell lines, whereas rapamycin and PD98059 had a moderate effect, with only 15 to 25% inhibition of thymidine incorporation. Both IL-6 and IGF-1 moderately increased cell proliferation, but inhibition of PI 3-K with LY294002 similarly inhibited cell-proliferation in the presence of these cytokines (data not shown).
Constitutive activation of the PI 3-K/Akt, mTOR/P70 S6K and ERK1/2 MAPK pathways are observed in MM cell lines
The activation of the PI 3-K pathway was studied in growth factor-independent cell lines through the phosphorylation of its downstream target, the serinethreonine kinase Akt (Ser 473). Figure 2a shows that both cell lines expressed a constitutively phosphorylated form of Akt on Ser473. Moreover, the Akt substrate Forkhead member FKHRL-1 was also spontaneously phosphorylated on Thr 32, highly suggesting that the Akt kinase is functionally active in these cells. The specificity of Akt phosphorylation downstream of PI 3-K activation was confirmed by inhibition of Ser 473 phosphorylation after treatment with LY294002 at 50 mM (Figure 2a ). We studied PTEN expression in both cell-lines (Figure 2a ). No expression of PTEN was detected in OPM2 as previously reported (Ge and Rudikoff, 2000a; Hyun et al., 2000) , whereas high expression of a normal size PTEN protein was present in RPMI8226 indicating that PI 3-K activity is not related to PTEN loss in this cell line.
Constitutive phosphorylation of P70 S6K protein on Thr 389, which is critical for kinase function in vivo, was detected ( Figure 2a ). LY294002 completely inhibited P70 S6K phosphorylation. Stimulation by IGF-1 at 100 ng/ml strongly enhanced the phosphorylation of Akt, FKHRL-1 and P70 S6K (Figure 2a ), whereas IL-6 at 100 ng/ml had no effect (data not shown).
In order to confirm the involvement of the PI 3-K pathway, we performed a biochemical analysis of phosphorylation of Akt, FKHRL-1 and P70 S6K in OPM2 cells treated by various concentrations of LY294002 or rapamycin. Figure 2b shows that a dose-dependent inhibition of the phosphorylation of these proteins by LY294002 could be observed. As expected, rapamycin did not modify Akt phosphorylation but completely inhibited P70 S6K phosphorylation.
The ERK-1/2 MAPK are constitutively activated in OPM2 and RPMI8226 MM cell lines, but independently of the PI 3-K pathway A role of the MAPK pathway activation has been suggested in IL-6-mediated cell-proliferation and survival in MM (de Vos et al., 2000; Ogata et al., 1997) . Figure 3 illustrates that the ERK-1/2 MAPK are spontaneously phosphorylated in OPM2 and RPMI8226 cells. This phosphorylation is reduced by the MAPK inhibitor PD98059 at 10 mM but not by LY294002 at 50 mM. These results and those reported in Figure 1a indicate that MAPK activation has no role in the proliferation of these factor-independent myeloma cell lines. Moreover, the dramatic effect of PI 3-K inhibition on their proliferation cannot be explained by an inhibition of the ERK1/2 proteins by LY294002.
The PI 3-K/Akt and mTOR/P70 S6K pathways are constitutively activated in freshly isolated plasmocytes from patients with MM and not related to PTEN loss
In order to determine the in vivo relevance of PI 3-K activation observed in MM cell lines, we studied six a b Figure 2 The PI 3-K/Akt/FKHRL1 and mTOR/P70 S6K pathways are constitutively activated in myeloma cell lines. (a) OPM2 and RPMI8226 cells were cultured at 10 7 /ml in serum free medium for 2 h at 378C with or without LY294002 50 mM. After deprivation, cells were stimulated or not with IGF-1 at 100 ng/ml for 20 min. Total cell lysates corresponding to 50 mg of proteins were subjected to WB analysis using either antibodies anti phosphospecific Akt (Ser 473), phosphospecific FKHRL-1 (Thr 32) or phosphospecific P70 S6K (Thr 389). Total cell lysates from both cell lines were studied for PTEN expression using WB analysis. (b) OPM2 cells were cultured in the same conditions with various concentrations of LY294002 ranging from 6 to 100 mM or Rapamycin ranging from 10 to 100 ng/ml. Equivalent amounts of proteins were loaded and analysed by WB using anti-phosphospecific Akt (Ser 473), anti-phosphospecific FKHRL-1 (Thr 32) or antiphosphospecific P70S6K (Thr 389) antibodies. Results are shown here only for OPM2 cell line
Role of the PI 3-K/Akt pathway in multiple myeloma F Pene et al patients for Akt, FKHRL-1 and P70 S6K phosphorylations. Four patients had intramedullar MM (MM1, 2, 3, 4), two at diagnosis and two at relapse. Two other patients presented at diagnosis with primary plasma cell leukemias (PCL1, PCL2) (Table 1) . Mononuclear cells obtained after Ficoll contained more than 90% of plasmocytes in PCL patients. Bone marrow plasmocytes from patients with intramedullar MM were positively selected with an anti-CD138 IgG-1 antibody coupled to magnetic beads. Purity of these plasmocytes ranged between 90 and 98%.
Plasmocytes from three out of six MM patients including the two patients with PCL (MM1, PCL1 and PCL2) had constitutive phosphorylation of Akt, FKHRL-1 and P70 S6K proteins as shown in Figure 4 . These phosphorylations were enhanced by stimulation with IGF-1 as previously described in myeloma cell lines. In patients MM2, MM3 and MM4, no constitutive phosphorylation was detected but Akt phosphorylation was induced with IGF-1 stimulation (data not shown). These results indicate that constitutive activations of the PI 3-K/Akt and mTOR/P70 S6K signaling pathways are frequent events in vivo in patients with MM, and may be especially observed in patients with aggressive disseminated forms of the disease (Table 1 ). All three patients with constitutive Akt phosphorylation had normal expression of PTEN (Figure 4) .
Activation of the PI 3-K/Akt pathway in OPM2 and RPMI8226 cell lines is not related to autocrine Il-6 production Autocrine production of IL-6 has been reported in myeloma cell lines. Such a mechanism may be implicated in PI 3-K activation observed in OPM2 and RPMI8226 cells. In order to examine this point, we first studied STAT3 activation. The STAT3 transcription factor was phosphorylated on Tyr 705 in OPM2 but not in RPMI8226 cells, and LY294002 did not modify STAT3 phosphorylation in OPM2 (Figure 5a ). Given that no activation of STAT3 could be detected in RPMI8226, we excluded the possibility that IL-6 was produced by this cell line.
We then used a neutralizing human anti-IL-6 antibody. This antibody did not modify the phosphorylation of Akt on Ser 473 in OPM2 (Figure 5a ). Finally, we found that the anti-IL-6 antibody had no effect on OPM2 proliferation (Figure 5b ).
Figure 3 Constitutive ERK1/2 MAPK activation is detected in myeloma cell lines but is independent of the PI 3-K pathway. OPM2 and RPMI8226 cells were cultured at 10 7 /ml in serum free medium for 2 h at 378C with or without MAPK inhibitor PD98059 at 10 mM (upper panel) or LY294002 50 mM (lower panel). Total cell lysates corresponding to 50 mg of proteins were subjected to WB analysis using an antibody recognizing the phosphorylated ERK1/ERK2 MAPK proteins MM1-2-3-4 are patients with MM. PCL1 and PCL2 are patients with primary plasma-cell leukemia. diag=status of the disease at the moment of the study, R=relapse, D=diagnosis is frequently observed in primary plasmocytes from patients with multiple myeloma or plasma-cell leukemia and not related to PTEN loss. Plasmocytes from four patients with intramedullar MM and two patients with PCL were obtained as indicated in Materials and methods. Cells were cultured for 12 h in RPMI medium supplemented with 15% FCS and washed twice in PBS. Cells were treated similarly as in Figure 2a . Total cell lysates corresponding to 100 mg of proteins were analysed by WB for the expression of the phosphorylated forms of Akt, FKHRL-1 and P70 S6K proteins (upper panel). Total cell lysates were also analysed for PTEN expression. Plasmocytes from patients with PCL (PCL1, PCL2) and from one out of four patients with MM (MM) are presented Role of the PI 3-K/Akt pathway in multiple myeloma F Pene et al
Inhibition of the PI 3-K pathway induces caspasedependent apoptosis
Akt phosphorylation in response to PI3-K activation has been shown to mediate anti-apoptotic signals. Indeed, exposition to LY294002 at 25 mM induced apoptosis in OPM2 and RPMI8226 cell lines. The percentage of annexin-V-PE positive cells increased significantly at 24 h with more than 30% of apoptotic cells under LY294002 and about 60% at 48 h, compared to 4 -10% in controls (Figure 6a ). Rapamycin at 25 ng/ml also induced moderate but significant apoptosis at 48 h of incubation (Figure 6a ). LY294002-induced apoptosis was a caspase dependent event. Figure 6b indicates that apoptosis induced by LY294002 was significantly, but not completely inhibited in the presence of the pan-caspase inhibitor Z-VAD-FMK at 100 mM. Control cells cultured in the presence of Z-VAD-FMK alone were viable ( Figure  6b ). Similar results were obtained in RPMI8226 (data not shown). Furthermore, LY294002 at 25 mM induced a time-dependent activation of the pro-caspase-3 as assessed by appearance of the cleaved-caspase-3 fragments (Figure 6c ). In growing non apoptotic cells cultured in the absence of LY294002, the only 28 kDa detectable band corresponded to the uncleaved procaspase-3 protein (Figure 6c ).
Inhibition of PI 3-K cooperates with Fas-induced apoptosis but apoptosis resulting from PI 3-K inhibition does not implicate the Fas/Fas-ligand system
We investigated whether inhibition of the PI 3-K pathway could cooperate with a Fas-mediated apoptosis pathway. OPM2 and RPMI8226 do express the Fas protein as assessed by flow cytometry analysis (data not shown). Fas receptor-induced aggregation by the agonistic anti-Fas antibody CH11 at 100 ng/ml induced apoptosis in both cell lines compared to controls without CH11 (Figure 7a ). The PI 3-K pathway has been shown to negatively modulate Fasligand expression by inactivating the transcriptional activity of the FKHRL-1 protein on the Fas-ligand promoter. The addition of both LY294002 at 25 mM and CH11 at 100 ng/ml significantly enhanced apoptosis as compared to that obtained with either compound added alone (Figure 7a ). We then studied if the modulation of PI-3K activity with either LY294002 or IGF-1 could modulate Fas ligand expression. Both cell lines spontaneously express the Fas-ligand protein. However, in our experimental conditions, neither the complete inhibition by LY294002 nor the full activation by IGF-1 of the PI 3-K pathway could modulate Fas-ligand expression. These results are reported in Figure 7b for OPM2, but were similar in RPMI8226. Moreover, LY294002-induced apoptosis was not inhibited by adding a chimeric Fas-Fc protein able to inhibit the interaction of Fas with its ligand (data not shown). These results suggest that PI 3-K-mediated inhibition of apoptosis is independent of the Fas/Fas-ligand system in these cell lines.
Inhibition of the PI 3-K pathway induces a G0/G1 cell cycle arrest and up-regulates p27
Kip1 expression with concomitant down regulation of Skp2 and cyclin D1 expression Inhibition of the PI 3-K pathway has been shown to cause cell-cycle arrest and up-regulation of the p27 Kip1 protein (13,29). In both OPM2 and RPMI8226 cells, LY294002 induced a significant increase of the percentage of cells in the G0/G1 phase of the cell cycle at 24 and 48 h and a concomitant decrease of cells in the S and G2/M phases (Figure 8a ). Apoptosis was induced as evidenced by an significant increase in the percentage of cells in the subG1 fraction (3% in OMP2 vs 14% in OPM2+LY294002) (Figure 8a ). Mitochondrial apoptosis was also induced by c a b Figure 5 Activation of the PI 3-K/Akt pathway in OPM2 and RPMI8226 cell lines is nort related to autocrine Il-6 production. (a) OPM2 and RPMI8226 cells were cultured at 10 7 /ml in serum free medium for 2 h at 378C with or without LY294002 50 mM. Total cell lysates corresponding to 50 mg of proteins were subjected to WB analysis using anti phosphospecific STAT3 (Tyr705) or anti STAT3 antibodies. (b) OPM2 cells were cultured with an neutralizing anti-IL-6 antibody at 0.05, 0.5 or 5 mg/ml and total cells lysates were subjected to WB analysis using an anti-phosphospecific Akt (Ser 473) antibody. (c) OPM2 cells were cultured in triplicate at 10 5 /ml in RPMI supplemented with 5% FCS for 48 h with either LY294002 at 50 mM or a neutralizing human anti-IL-6 antibody at 0.05, 0.5, or 5 mg/ml. DNA synthesis was assessed by [ 3 H]thymidine incorporation after 6 h Role of the PI 3-K/Akt pathway in multiple myeloma F Pene et al LY294002 with 7% of DiOC 6(3) negative ( m low) cells without LY294002 vs 46% when PI 3-K activity was inhibited (Figure 8a ). Both cell lines express high levels of cyclin D1 protein and LY294002 at 50 mM diminished cyclin D1 expression (Figure 8b) . Moreover, high level of Skp2 expression in growing OPM2 and RPMI8226 cell lines was dramatically inhibited in the presence of LY294002. We then studied expression of the cell cycle inhibitor p27 Kip1 . p27 Kip-1 expression was low or even undetectable in proliferating cells but highly upregulated in the presence of LY294002 at 24 and 48 h /ml in RPMI with 5% FCS in the presence or not of LY294002 at 25 mM or rapamycin at 25 ng/ml. Three separate experiments were performed. Results are given for one experiment at 48 h of incubation with the inhibitors. (b) OPM2 cells were plated at 10 5 /ml in RPMI with 5% FCS in the presence of either LY294002 at 25 mM, the broad spectrum caspase-inhibitor Z-VAD-FMK at 100 mM or both added simultaneously. Results are given at 24 h of incubation. (c) OPM2 cells were cultured at 10 5 /ml in RPMI with 5% FCS in the presence or not of LY294002 at 25 mM for 24, 48 or 72 h. Total cell lysates corresponding to 50 mg of proteins were analysed by WB using anti-caspase-3 antibody Role of the PI 3-K/Akt pathway in multiple myeloma F Pene et al ( Figure 8b ). These results suggest that the PI 3-Kmediated proliferation observed in these MM cell lines may be explained by the concomitant high level of cyclin D1 and low level of p27 KIP1 proteins, driving cells into the cell cycle. Moreover, spontaneous phosphorylation at high level of the a and b isoforms of the GSK3 protein was detected in the OPM2 cell line and inhibited by LY204002 but not by rapamycin (Figure 8c ). PI 3-K-mediated phosphorylation of the GSK3 protein inhibits its function and may contribute to elevated cyclin D1 expression that induces high proliferation rate (Takuwa et al., 1999) . PI 3-Kmediated high level expression of Skp2 may lead to proteasome-mediated degradation of p27 Kip1 as previously described (Mamillapalli et al., 2001) .
Discussion
In our study, we provide evidence that constitutive activation of the PI 3-K/Akt signaling pathway frequently occurs in MM in vivo. Moreover, we found that inhibition of the PI 3-K/Akt pathway dramatically affects the growth and survival of growth factora b Figure 7 LY294002-induced apoptosis does not involve the Fas/Fas-Ligand system but has additive effects with-Fas mediated apoptotic pathway. (a) OPM2 and RPMI8226 cells were plated at 10 5 /ml in RPMI with 5% FCS in the presence of either LY294002 at 25 mM, the agonistic anti-Fas antibody CH11 at 100 ng/ml or both compounds added simultaneously. Apoptosis was quantified using flow cytometry analysis of the percentage of annexin-V-PE positive cells from the whole population at 24 and 48 h. Results are given at 24 h. Two different experiments were performed. (b) OPM2 cells were cultured at 10 5 /ml in RPMI with 5% FCS with or without LY294002 at 50 mM for 6, 12, 24 and 48 h. Total cell lysates corresponding to 50 mg of proteins for each point were analysed by anti Fas-Ligand immunoblotting (upper panel). Fas-Ligand expression was also studied at 24 and 48 h after stimulation with IGF-1 at 100 ng/ml (lower panel)
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Kip1 proteins expression by PI 3-K activity may be critical for the control of proliferation and survival of MM cells.
IL-6 and IGF-1 are important paracrine stimuli for plasmocytes growth (Ferlin et al., 2000; Freund et al., 1993; Ge and Rudikoff, 2000b; Klein et al., 1995) . IL-15 may also have an autocrine role in the biology of MM (Tinhofer et al., 2000) . The MAPK pathway may be involved in the proliferation of both growth factorindependent and IL-6-dependent myeloma cell lines (Ogata et al., 1997) . IL-6 increases myeloma growth by triggering the Ras/Raf/MAPK cascade, and inhibition of the MAPK and STAT pathways with the JAK2 tyrosine kinase inhibitor tyrphostin AG490 suppresses cell proliferation and induces apoptosis in an IL-6-dependent myeloma cell line (de Vos et al., 2000) . The anti-apoptotic activity of the JAK/STAT pathway has also been suggested. Constitutive activation of STAT3 observed in U266 myeloma cells explains the high expression of the anti-apoptotic protein Bcl-X L , through STAT3-mediated transactivation of the Bcl-XL promoter (Catlett-Falcone et al., 1999) . The JAK/ STAT pathway activated by IL-6 may also control cell survival by upregulation of the anti-apoptotic mcl-1 protein (Puthier et al., 1999) .
Activation of the PI 3-K/Akt pathway in response to IL-6 and IGF-1 has been described in MM (Hideshima et al., 2001; Tu et al., 2000) . Recent data using immunohistochemistry performed on bone marrow smears detected phospho-Akt staining in patients with stade III MM but not in patients with smoldering myeloma or monoclonal gammapathy of undetermined significance (Hsu et al., 2001) . This suggests that Akt may be important in the biology of MM in vivo.
In this work, we have studied the activity and functional consequences of PI 3-K activation in the biology of growth factor-independent myeloma cells. We found that PI 3-K is frequently activated, as confirmed by the detection of constitutive phosphorylation of different substrates downstream of PI 3-K, including Akt, FKHRL-1, P70 S6K and GSK-3 in two myeloma cell lines. Moreover, constitutive activation of the PI 3-K/Akt pathway was detected in freshly purified plasmocytes from three out of six patients with either PCL or intramedullar MM.
The MAPK pathway was also constitutively activated in these cell lines but LY294002 did not modulate ERK1/2 phosphorylation, suggesting that MAPK activation is independent of PI 3-K. Moreover PD98059, a specific MAPK inhibitor, moderately inhibited DNA synthesis, suggesting that this pathway has not a major role in the control of proliferation in these cell lines.
The oncogenic role of the deregulated PI 3-K pathway is probably related to its simultaneous actions on cell growth and survival. Different mechanisms of PI 3-K/Akt deregulation and activation have been reported in different systems. Amplification of the p110 subunit of PI 3-K is observed in ovarian cancer (Shayesteh et al., 1999) . Akt2 is overexpressed in ovarian and pancreatic carcinomas (Cheng et al., 1996) and the active catalytic p110 subunit of PI 3-K found in a chicken tumor virus mediates its transforming effects through Akt (Chang et al., 1997) . In addition, Figure 2a . Total cell lysates corresponding to 50 mg of proteins were analysed by WB for the phosphorylated and native forms of the GSK-3 protein inactivating mutations in the tumor-suppressor gene PTEN, a negative regulator of PI 3-K activity, can explain Akt hyperactivity by increased levels of 3'-phosphoinositides. Loss of PTEN expression as a result of internal deletions of PTEN gene explains PI 3-K activation in 47 and OPM2 human myeloma cell lines (Ge and Rudikoff, 2000a; Hyun et al., 2000) . We did not detect PTEN loss in RPMI8226 cells and in any of the three patients with active PI 3-K (MM1, PCL1 and PCL2), indicating that additional mechanisms downstream of PTEN contribute to PI 3-K deregulation in these patients. Autocrine IL-6 production as a mechanism of PI 3-K activity was also excluded in the two cell lines.
Some of the oncogenic effects of PI 3-K may be mediated through the mTOR/P70 S6K pathway. P70 S6K seems essential for the G1/S transition of the cell cycle (Lane et al., 1993) . Some studies have suggested an oncogenic potential for the mTOR/P70 S6K pathway (Aoki et al., 2001; Mahalingam and Templeton, 1996) . The activation of the IRS2/PI 3-K/P70 S6K pathway has been demonstrated in murine plasma-cell tumors induced by chemicals or by oncogene-containing retroviruses . Our results shows that activation of the mTOR/P70 S6K is observed in human myeloma cell lines and in vivo in primary purified plasmocytes. Phosphorylation of P70 S6K protein on Thr 389 was easily detectable in OPM2 and RPMI8226 cell lines and strongly induced in response to IGF-1 stimulation. We also show that a constitutive activation of P70 S6K was detected in the three out of six patients with myeloma having constitutive phosphorylation of Akt/FKHRL-1. Inhibition of the mTOR/P70 S6K pathway by biochemically active concentrations of rapamycin had a moderate effect on the proliferation of OPM2 and RPMI8226, even in the presence of IGF-1 (data not shown), whereas this compound induced significant apoptosis. These results indicate that selective inhibition of this pathway has not a important role in the control of cell proliferation but may be involved in apoptosis. Indeed, rapamycin has been reported to induce apoptosis in some cell types (Hosoi et al., 1999; Shi et al., 1995) . A mechanism linking P70 S6K activity to the control of cell survival has been recently suggested, as P70 S6K was identified as a BAD Ser 136-specific kinase (Harada et al., 2001) .
In contrast, LY294002 that inhibits PI 3-K had dramatic effects on cell proliferation. This effect was also observed after stimulation by IL-6 and IGF-1 at high concentrations. However, only IGF-1 but not IL-6 increased Akt, FKHRL-1 and P70 S6K phosphorylations. The role of PI 3-K may be explained through the activation of Akt substrates FKHRL-1 and GSK3. In the presence of LY294002, p27
Kip1 expression was induced in OPM2 and RPMI8226. Part of this positive regulation may take place at the transcriptional level and recent data suggest that even a mild increase in transcription of the p27 Kip1 gene may be sufficient to induce cell-cycle arrest and increase the half life of the protein (Nakamura et al., 2000) . However, our results suggest that post-transcriptional regulation of p27 Kip1 protein may also occur. Both myeloma cell lines expressed high levels of Skp2. It was recently shown that Skp2 expression is positively regulated by a PTEN/PI 3-K pathway (Mamillapalli et al., 2001) . Our results are in accordance with this model as LY294002 strongly down-regulated Skp2 expression. In human Non Hodgkin Lymphomas and particularly diffuse large B-cell lymphomas, Skp2 expression also correlates with the grade of malignancy and is inversely related with P27 Kip1 levels (Latres et al., 2001) . Concomitant high expression of Skp2 and low P27 Kip1 expression might be observed in MM patients with spontaneous PI 3-K activity. PI 3-K-mediated control of cyclin D1 expression may also promote cell growth. Both OPM2 and RPMI8226 expressed high levels of cyclin D1 which was downregulated by LY294002. Interestingly, intense GSK-3 phosphorylation was detected in OPM2 cells. Akt-induced GSK-3 phosphorylation inhibits its activity and abolishes bcatenin phosphorylation. Unphosphorylated b-catenin is then translocated to the nucleus where it induces transcription of many genes including cyclin D1 (Morin, 1999) . Moreover, cyclin D1 is also stabilized at a post-transcriptional level, owing to decreased phosphorylation at a GSK-3 site promoting proteolytic turnover of cyclin D1 (Diehl et al., 1998) .
PI 3-K also controlled the survival of these cell lines and inhibition of Akt phosphorylation resulted in apoptosis implicating the mitochondria. The role of Akt in the control of cell survival is well known and most of the anti-apoptotic effects may be mediated by FKHRL-1. The unphosphorylated form of FKHRL-1 has been shown to promote transcription of the Fasligand gene . However, PI 3-K modulation did not modified Fas-ligand expression and inhibiting Fas/Fas-ligand interaction with a Fas-Fc chimeric protein did not modify LY294002-induced apoptosis, suggesting that signaling pathways other than PI 3-K may regulate Fas-Ligand expression in MM. This apoptosis was caspase-dependent as demonstrated by Z-VAD-FMK-mediated inhibition and cleavage of the native caspase-3 protein in LY294002-induced apoptotic cells. Some links between Akt activation and caspase inhibition exist. Akt-induced phosphorylation of pro-caspase-9 inhibits its protease activity (Cardone et al., 1998) . Akt may also inhibit cell-death by preventing the release of cytochrome c from mitochondria and the processing of pro-caspases to their active form, linking PI 3-K to the control of mitochondria. (Kennedy et al., 1999) . Akt-induced BAD Ser 136 phosphorylation may have an additive role in survival (Datta et al., 1997) . In human IL-6-dependent myeloma cell line MM.1S, IL-6 induces PI 3-K dependent phosphorylation of BAD (Hideshima et al., 2001) . Alternatively, high p27
Kip1 expression in response to PI 3-K inhibition may be central for the control of proliferation and apoptosis. The biological mechanisms implicating p27
Kip1 in the control of survival are not clear but overexpression of this protein leads to apoptosis in IL-3-dependent BaF/3 cells (Parada et al., 2001) . Moreover, enforced high p27 Kip1 expression in primary cells from patients with T-cell acute lymphoblastic leukemia prevent cell cycle progression and induces apoptosis (Barata et al., 2001) . A similar situation may be relevant in MM.
The biological mechanisms that lead to PI 3-K deregulated activation are unknown in MM. They seem to generally stand downstream of PTEN. Understanding them may help develop specific therapeutic tools to inhibit this pathway which seems to dramatically control both proliferation and survival.
Materials and methods

Cell lines and patients
OPM2 and RPMI8226 are human factor-independent cell lines, cultured in RPMI 1640 medium supplemented with 15% fetal calf serum (FCS). All cell lines were kindly provided by JC Brouet (Hematology Institute of Paris VII University, Hoˆpital Saint-Louis, Paris, France).
Plasmocytes from six patients with multiple myeloma (n=4) and primary plasma-cell leukemia (PCL) (n=2) were studied. The clinical and biological features of their diseases are shown in Table 1 . Bone marrow aspirates or peripheral blood, obtained after informed consent, were submitted to a Ficoll density gradient. The low density cells were typed for the expression of CD38 and CD138 antigens with a fluorescence analysis. In samples obtained from bone marrow, CD138-expressing cells were separated by positive selection using an immuno-magnetic procedure (MACS; Milteny Biotech, Auburn, CA, USA) controlled by a CD 138 FACS typing, and cultured for 24 h in RPMI 1640 medium supplemented with 15% FCS. In the two patients with PCL, pure populations of plasmocytes were obtained after Ficoll and positive selection was not necessary.
FISH analyses were performed from the peripheral blood or bone marrow sample processed for karyotype. Del(13q) / 713 was tested with a dual color FISH kit (Cytocell/ Aquarius, UK) composed of a 13q14.3 probe (D13S319, D13S25) and a 13qter controˆle probe. In patient PCL2, der(14)t(11;14) was tested for IGH-CCND1 fusion with a dual color FISH kit (Vysis, USA) containing a mixture of CCND1 (11q13) and IGH (14q32) probes. In all cases FISH experiments were performed according to the recommandations of the kit supplier.
Antibodies and reagents
Phosphospecific Akt (Ser473), phosphospecific P70 S6K (Thr389), phosphospecific ERK-1/ERK-2, phosphospecific STAT3 and phosphospecific GSK-3ab antibodies were purchased from Cell Signaling 1 , Akt, Skp2, Cyclin-D1, PTEN and GSK-3a antibodies from Santa Cruz Biotechnology 1 , Caspase-3 and Fas-Ligand (NOK1) antibodies from Pharmingen 1 , phosphospecific FKHRL-1 (Thr 32) and FKHRL1 from Upstate Biotechnology 1 , P27 Kip-1 and anti-STAT3 antibodies from Transduction Laboratories 1 . The Fas antibody CH11 was purchased from Immunotech.
IGF1, LY294002, Wortmannin and Rapamycin were purchased from Sigma 1 and PD98059 from New England Biolabs 1 . The large spectrum caspase inhibitor ZVAD-FMK was purchased from Bachem 1 . The monoclonal anti-human IL-6 antibody was from R&D systems.
Cell growth assays
DNA synthesis was measured by thymidine incorporation. Briefly, after three washes in PBS, cells were resuspended at 10 5 /ml in RPMI containing 5% FCS, and incubated for 48 h in 96-well flat-bottomed plates in the presence or absence of various concentrations of inhibitors (LY294002, Wortmannin, rapamycin, anti human-IL-6 neutralizing antibody or PD98059). After 48 h of culture, cells were pulsed with [ 3 H]thymidine for 4 h in order to determine the amount of radioactivity incorporated in the cells.
Preparation of cell extracts and Western blot analysis
Before each experiment, cells were washed twice in phosphate buffered saline (PBS) then cultured in adequate medium. For the analysis of phosphorylation of Akt, FKHRL1, P70 S6K and MAPK proteins, cells were washed three times in PBS and starved for 2 h in Iscove's Dulbecco's modified eagle medium (DMEM) containing 0.1% bovine serum albumin and 25 mg/ml iron-loaded human transferrin with or without LY294002, then stimulated or not by IGF-1 (100 ng/ml) for 20 min at 378C. For other experiments, cells were plated at 10 5 /ml in RPMI1640 medium supplemented with 5% FCS. The experiment was stopped by diluting the cells with ice-cold PBS containing 50 mmol/l sodium vanadate. Cells were solubilized with buffer A containing 1% Brij 98 (buffer A: 10 mM Tris/HCl, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1 mM sodium vanadate, 0.02% NaN 3 and protease inhibitors from Roche 1 (cat. number 1873580). Protein extracts were quantified using commercial kit BCA protein assay (Pierce 1 ). Samples containing 50 to 100 mg protein were then boiled in Laemmli sample buffer, separated by SDS -PAGE and analysed by Western blot (WB) using adequate antibodies. The chemoluminescence kit ECL (Amersham Pharmacia Biotech 1 ) was used for revelation.
Analysis of apoptosis
Cells were cultured at 10 5 /ml in RPMI1640 medium containing 5% FCS, with or without LY294002 at 50 mM and in the presence or not of the caspase-inhibitor Z-VAD-FMK at 100 ng/ml, or of the activator anti-Fas antibody CH 11 at 100 mg/ml. Apoptosis was quantified by FACS analysis on a XL cytometer (Coulter 1 ) of the percentage of Annexin-V-PE positive cells in the whole population at 24 and 48 h. In some experiments, mitochondrial apoptosis was quantified. Apoptotic cells with a drop in mitochondria transmembrane potential were DiOC 6(3) negative, namelly DC m low.
Cell cycle analysis
Cell lines were cultured for 24 or 48 h in RPMI1640 medium supplemented with 5% FCS and subjected to DNA staining by propidium iodure. The percentage of cells for each different cycle phase was determined by FACS analysis.
